INNOVATIVE PRODUCTS

Tosk has patented two new pharmaceutical products and has two other preclinical-stage products in development.

TK-90: Our most advanced, patented drug — now in human clinical trials — is targeted at mucositis side effect reduction. Mucositis is the painful inflammation and ulceration of the mucous membranes lining the mouth, throat, and digestive tract, usually as an adverse effect of chemotherapy or radiation. Mucositis is costly to treat and may result in affecting or even terminating optimum treatment. Oral mucositis, inflammation and ulceration that occurs in the mouth, is a common and often debilitating complication of cancer treatment. Mucositis in the gut can introduce a route of infection that can be debilitating and potentially fatal.

Mucositis is a common side effect of cancer therapies. Mucositis is costly to treat and may result in affecting or even terminating optimum treatment.

TK-39: Tosk’s second patented product has been developed to block the cardiotoxicity that results from a class of widely used cancer drugs known as anthracyclines. This damage to heart tissue is permanent and limits the lifetime dose of these drugs. Many patients are forced to suspend treatment due to this adverse effect. Anthracyclines are used to treat breast, bladder, and lung cancers as well as lymphoma and leukemia. Even at the lifetime limited dose, as many of 50% of patients suffer reduced heart function later in life.

TK-88: Our third drug discovery initiative is designed to block the damage that widely used platinum-based drugs, such as cisplatin and carboplatin, can cause. These adverse effects can be permanent and include kidney damage, peripheral neuropathy, and hearing loss.

TK-kRAS: This effort addresses a gene found in up to 40 percent of cancer patients that renders certain cancer drugs, known as EGFR inhibitors ineffective. The first objective of this project is to make these drugs effective in patients.

Drugs emerging from the TK-kRAS effort also have the potential to treat kRAS-positive cancers, including 90% of pancreatic cancers, 45% of colon cancers, and 35% of lung cancers. We are collaborating in this effort with the National Cancer Institute and Dr. Jeffrey Thomas’ laboratory at the Texas Tech University Health Sciences Center.

There are very few early stage biopharma companies with four drugs in the pipeline.